News Release
![]() |
<< Back |
![]() |
Cidara Therapeutics to Present Data on Novel Antifungal CD101 and Cloudbreak Antibacterial Immunotherapy at ECCMID and SID Annual Meetings
|
“These presentations highlight the potential of our CD101 and Cloudbreak
platforms to address the unmet need for new therapeutic approaches to
treat and prevent fungal and bacterial infections -- particularly those
that are resistant to existing anti-infectives,” said
A total of five presentations, comprising one oral presentation and four posters, will highlight data evaluating the potential of Cidara’s lead drug candidates, CD101 and CD201, to treat and prevent serious infections. The ECCMID presentations include data on CD101 in Candida auris, an emerging virulent fungal infection, as well the compound’s potential for use as a subcutaneous formulation for prophylactic treatment in candidiasis and aspergillosis. Data from studies related to the antibacterial activity of CD201 in Gram-negative bacterial infections will also be presented at ECCMID. Finally, the SID presentation will include data on the efficacy of CD101 as a potential treatment for dermatophytosis and onychomycosis, fungal infections of the skin and nails.
Details of the Cidara ECCMID and SID 2017 presentations are as follows:
ECCMID 2017 Presentations |
Oral Presentation: |
Title: In-vitro characterization of antibacterial activity,
cidality and spontaneous resistance potential of CD201, |
Date and time: Monday, April 24 from 10:24 a.m. – 10:34 a.m. Central European Daylight Time (CEDT) |
Location: Reed Messe Wien, Hall K |
Presentation number: OS0566 |
Session: New drugs against Gram-negatives: from discovery to late-stage development |
Poster Presentations: |
Title: Susceptibility of recent Candida auris isolates to
the novel echinocandin CD101 and comparator |
Date and Time: Saturday, April 22 from 8:45 a.m. – 3:30 p.m. CEDT |
Location: Reed Messe Wien, ePoster Viewing Area |
Presentation number: EV0128 |
Session: Fungal infection & disease |
Title: Antibacterial activity of CD201, a novel
lipopolysaccharide-binding antibacterial immunotherapy, |
Date and time: Saturday, April 22 from 3:30 p.m. – 4:30 p.m. CEDT |
Location: Reed Messe Wien, Paper Poster Area |
Presentation number: P0475 |
Session: New antibody and immunomodulatory approaches |
Title: Prophylactic, single-dose, subcutaneous (SC)
administration of CD101 shows robust efficacy |
Date and time: Monday, April 24 from 1:30 p.m. – 2:30 p.m. with ePoster Discussion from 2:06 p.m. – 2:11 p.m. CEDT |
Location: Reed Messe Wien, ePoster Arena 5 |
Presentation number: EP0703 |
Session: Candida infections: from changing epidemiology to changing treatment |
All ECCMID abstracts are available on the conference website at www.eccmidlive.org.
SID 2017 Poster Presentation |
Title: Efficacy of CD101, a novel echinocandin, in the
treatment of dermatophytosis |
Date and time: Friday, April 28 from 12:00 p.m. – 1:00 p.m. Pacific Daylight Time |
Location: Oregon Convention Center, Exhibit Hall A Foyer |
Abstract number: 689 |
Session: Selected ePoster Discussion II – Pharmacology and drug development |
Copies of these presentations and posters will be available on the Cidara website following the meetings: http://www.Cidara.com/
About
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, CD101 IV, through Phase 2
and developing CD201, its bispecific antibiotic immunotherapy, for the
treatment of multi-drug resistant Gram-negative bacterial infections.
CD101 IV has enhanced potency and is the only once-weekly therapy
intended for the treatment and prevention of life-threatening invasive
fungal infections. CD201 is the first drug candidate selected from
Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery
platform designed specifically to create compounds that direct a
patient’s immune cells to attack and eliminate bacterial, fungal or
viral pathogens. Cidara recently received a grant for up to
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effectiveness, safety, and other attributes
of CD101 and CD201 and other potential product candidates, including the
potential for these compounds to successfully treat fungal or bacterial
infections, including those caused by resistant pathogens, and
potentially transform the way infectious diseases are treated, and the
potential for the Cloudbreak platform to result in future drug
candidates. Risks that contribute to the uncertain nature of the
forward-looking statements include: the success and timing of Cidara’s
preclinical studies and clinical trials; regulatory developments in
View source version on businesswire.com: http://www.businesswire.com/news/home/20170417005290/en/
Source:
Cidara Therapeutics
INVESTORS
Westwicke Partners, LLC
Robert
H. Uhl, 858-356-5932
Managing Director
robert.uhl@westwicke.com
or
MEDIA
Sam
Brown Inc.
Christy Curran, 615-414-8668
ChristyCurran@sambrown.com